Retatrutide for Obesity

(TRIUMPH-8 Trial)

This trial tests the effectiveness and safety of a drug called retatrutide for weight loss. Participants will receive either retatrutide or a placebo (a treatment with no active drug) to compare the drug's effectiveness against no treatment. The trial seeks individuals with a BMI of 30 or higher, or a BMI of 27 or higher with conditions like high blood pressure or sleep apnea, who have struggled to lose weight through dieting. Participants will be involved for about 65 weeks and will attend around 18 visits. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking weight loss treatment.

The trial does not specify if you need to stop taking your current medications, but you cannot have taken weight loss drugs in the 90 days before screening.

Research has shown that retatrutide is generally safe for individuals with obesity. Studies have found that it aids in significant weight loss and is considered safe for adults with obesity. Most participants experienced expected side effects, such as mild nausea and diarrhea, which are common with similar treatments. No major safety issues have been reported. However, retatrutide has not yet received FDA approval for general use, so staying updated on any new safety information is important.¹²³⁴⁵

Retatrutide is unique because it targets obesity by acting on multiple hormone pathways, which is different from most current treatments that focus on a single pathway. This new mechanism of action could lead to more effective weight loss and improved metabolic health. Researchers are excited about Retatrutide because it offers the possibility of better results with fewer side effects compared to existing options like GLP-1 receptor agonists. Additionally, the subcutaneous delivery method of Retatrutide allows for potentially more consistent and sustained therapeutic effects.

Research has shown that retatrutide aids weight loss in people with obesity. In previous studies, participants experienced significant weight loss with this treatment. One study found that those on the highest dose lost an average of 16.9% of their body weight. Another study reported weight loss of up to 24.2% after 48 weeks. This trial will test different doses of retatrutide, and these findings suggest that retatrutide can significantly reduce body weight in people with obesity.¹²⁴⁶⁷